185 related articles for article (PubMed ID: 28007775)
21. mTOR inhibition by everolimus in childhood acute lymphoblastic leukemia induces caspase-independent cell death.
Baraz R; Cisterne A; Saunders PO; Hewson J; Thien M; Weiss J; Basnett J; Bradstock KF; Bendall LJ
PLoS One; 2014; 9(7):e102494. PubMed ID: 25014496
[TBL] [Abstract][Full Text] [Related]
22. Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway.
Lonetti A; Cappellini A; Bertaina A; Locatelli F; Pession A; Buontempo F; Evangelisti C; Evangelisti C; Orsini E; Zambonin L; Neri LM; Martelli AM; Chiarini F
J Hematol Oncol; 2016 Oct; 9(1):114. PubMed ID: 27776559
[TBL] [Abstract][Full Text] [Related]
23. Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset.
Padi SKR; Luevano LA; An N; Pandey R; Singh N; Song JH; Aster JC; Yu XZ; Mehrotra S; Kraft AS
Oncotarget; 2017 May; 8(18):30199-30216. PubMed ID: 28415816
[TBL] [Abstract][Full Text] [Related]
24. Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance.
Bonapace L; Bornhauser BC; Schmitz M; Cario G; Ziegler U; Niggli FK; Schäfer BW; Schrappe M; Stanulla M; Bourquin JP
J Clin Invest; 2010 Apr; 120(4):1310-23. PubMed ID: 20200450
[TBL] [Abstract][Full Text] [Related]
25. Ribociclib, a Cdk4/Cdk6 kinase inhibitor, enhances glucocorticoid sensitivity in B-acute lymphoblastic leukemia (B-All).
Bortolozzi R; Mattiuzzo E; Trentin L; Accordi B; Basso G; Viola G
Biochem Pharmacol; 2018 Jul; 153():230-241. PubMed ID: 29408328
[TBL] [Abstract][Full Text] [Related]
26. Healthy CD4+ T lymphocytes are not affected by targeted therapies against the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia.
Alameen AA; Simioni C; Martelli AM; Zauli G; Ultimo S; McCubrey JA; Gonelli A; Marisi G; Ulivi P; Capitani S; Neri LM
Oncotarget; 2016 Aug; 7(34):55690-55703. PubMed ID: 27494886
[TBL] [Abstract][Full Text] [Related]
27. Targeting the mTOR Pathway in Leukemia.
Dinner S; Platanias LC
J Cell Biochem; 2016 Aug; 117(8):1745-52. PubMed ID: 27018341
[TBL] [Abstract][Full Text] [Related]
28. TKI258, a multi-tyrosine kinase inhibitor is efficacious against human infant/childhood lymphoblastic leukemia in vitro.
Eucker J; Zang C; Zhou Y; Li X; Habbel P; Schulz CO; Scholz C; Liu H
Anticancer Res; 2014 Sep; 34(9):4899-907. PubMed ID: 25202072
[TBL] [Abstract][Full Text] [Related]
29.
Teh JLF; Cheng PF; Purwin TJ; Nikbakht N; Patel P; Chervoneva I; Ertel A; Fortina PM; Kleiber I; HooKim K; Davies MA; Kwong LN; Levesque MP; Dummer R; Aplin AE
Cancer Discov; 2018 May; 8(5):568-581. PubMed ID: 29496664
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic potential of targeting mTOR in T-cell acute lymphoblastic leukemia (review).
Evangelisti C; Evangelisti C; Chiarini F; Lonetti A; Buontempo F; Bressanin D; Cappellini A; Orsini E; McCubrey JA; Martelli AM
Int J Oncol; 2014 Sep; 45(3):909-18. PubMed ID: 24968804
[TBL] [Abstract][Full Text] [Related]
31. Polo-like Kinase 4: the Variation During Therapy and its Relation to Treatment Response and Prognostic Risk Stratification in Childhood Acute Lymphoblastic Leukemia Patients.
Xu J; Zhao L
J Pediatr Hematol Oncol; 2023 May; 45(4):189-194. PubMed ID: 35973104
[TBL] [Abstract][Full Text] [Related]
32. Synergistic activity of rapamycin and dexamethasone in vitro and in vivo in acute lymphoblastic leukemia via cell-cycle arrest and apoptosis.
Zhang C; Ryu YK; Chen TZ; Hall CP; Webster DR; Kang MH
Leuk Res; 2012 Mar; 36(3):342-9. PubMed ID: 22137317
[TBL] [Abstract][Full Text] [Related]
33. MNK1 inhibitor CGP57380 overcomes mTOR inhibitor-induced activation of eIF4E: the mechanism of synergic killing of human T-ALL cells.
Huang XB; Yang CM; Han QM; Ye XJ; Lei W; Qian WB
Acta Pharmacol Sin; 2018 Dec; 39(12):1894-1901. PubMed ID: 30297804
[TBL] [Abstract][Full Text] [Related]
34. mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia.
Teachey DT; Sheen C; Hall J; Ryan T; Brown VI; Fish J; Reid GS; Seif AE; Norris R; Chang YJ; Carroll M; Grupp SA
Blood; 2008 Sep; 112(5):2020-3. PubMed ID: 18544682
[TBL] [Abstract][Full Text] [Related]
35. Resveratrol induces apoptosis and autophagy in T-cell acute lymphoblastic leukemia cells by inhibiting Akt/mTOR and activating p38-MAPK.
Ge J; Liu Y; Li Q; Guo X; Gu L; Ma ZG; Zhu YP
Biomed Environ Sci; 2013 Nov; 26(11):902-11. PubMed ID: 24331535
[TBL] [Abstract][Full Text] [Related]
36. Phase I trial of the mTOR inhibitor everolimus in combination with multi-agent chemotherapy in relapsed childhood acute lymphoblastic leukemia.
Place AE; Pikman Y; Stevenson KE; Harris MH; Pauly M; Sulis ML; Hijiya N; Gore L; Cooper TM; Loh ML; Roti G; Neuberg DS; Hunt SK; Orloff-Parry S; Stegmaier K; Sallan SE; Silverman LB
Pediatr Blood Cancer; 2018 Jul; 65(7):e27062. PubMed ID: 29603593
[TBL] [Abstract][Full Text] [Related]
37. Glucocorticoid resistance is reverted by LCK inhibition in pediatric T-cell acute lymphoblastic leukemia.
Serafin V; Capuzzo G; Milani G; Minuzzo SA; Pinazza M; Bortolozzi R; Bresolin S; Porcù E; Frasson C; Indraccolo S; Basso G; Accordi B
Blood; 2017 Dec; 130(25):2750-2761. PubMed ID: 29101238
[TBL] [Abstract][Full Text] [Related]
38. PI3K inhibition synergizes with glucocorticoids but antagonizes with methotrexate in T-cell acute lymphoblastic leukemia.
Silveira AB; Laranjeira AB; Rodrigues GO; Leal PC; Cardoso BA; Barata JT; Yunes RA; Zanchin NI; Brandalise SR; Yunes JA
Oncotarget; 2015 May; 6(15):13105-18. PubMed ID: 25869207
[TBL] [Abstract][Full Text] [Related]
39. Ribavirin Inhibits the Activity of mTOR/eIF4E, ERK/Mnk1/eIF4E Signaling Pathway and Synergizes with Tyrosine Kinase Inhibitor Imatinib to Impair Bcr-Abl Mediated Proliferation and Apoptosis in Ph+ Leukemia.
Shi F; Len Y; Gong Y; Shi R; Yang X; Naren D; Yan T
PLoS One; 2015; 10(8):e0136746. PubMed ID: 26317515
[TBL] [Abstract][Full Text] [Related]
40. PI3K/mTOR inhibition upregulates NOTCH-MYC signalling leading to an impaired cytotoxic response.
Shepherd C; Banerjee L; Cheung CW; Mansour MR; Jenkinson S; Gale RE; Khwaja A
Leukemia; 2013 Mar; 27(3):650-60. PubMed ID: 23038273
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
